| eribulin versus dacarbazine | |||
| Eribulin phase 3 (Schöffski ), 2016 | versus | patients aged 18 years or older with intermediate-grade or high-grade advanced liposarcoma or leiomyosarcoma who had received at least two previous systemic regimens for advanced disease (including an anthracycline) | |
| gemcitabine plus dacarbazine versus dacarbazine | |||
| Spanish Group for Research on Sarcomas , 2011 | versus | ||
| pazopanib versus placebo | |||
| PALETTE (van der Graaf), 2012 NCT00753688 | versus | ||
| trabectedin versus dacarbazine | |||
| Demetri, 2016 NCT01343277 | versus | patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen | |
| trabectedin versus SOC | |||
| TSAR, NCT02672527 | versus | ||
| trabectedin versus trabectedin | |||
| phase 2 ET743-STS-201 , NCT00060944 | versus | ||
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
